

NOTIFICATION OF PARTICIPATION AND FORM FOR POSTAL VOTING

in accordance with § 8 of Swedish Orphan Biovitrum AB (publ)'s Articles of Association.

To be received by Euroclear Sweden AB no later than Friday, 2 May 2025.

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, at the Annual General Meeting on Thursday, 8 May 2025. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this postal vote on behalf of the shareholder and that the contents of the postal vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions:

- Complete the information above.
- Select the preferred voting options below.
- Print, sign and send the form to Swedish Orphan Biovitrum AB (publ), “Annual General Meeting”, c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden. A completed and signed form may also be submitted electronically and shall, in such case, be sent to generalmeetingservice@euroclear.com. Shareholders may also cast their votes electronically through verification with BankID via Euroclear Sweden AB’s website <https://anmalan.vpc.se/euroclearproxy?sprak=1>.
- If the shareholder is a natural person who is personally voting by post, it is the shareholder who should sign under *Signature* above. If the postal vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the postal vote is submitted by a legal representative of a legal entity, it is the representative who should sign.
- If the shareholder submits its postal vote by proxy, a power of attorney must be enclosed with the postal voting form. Powers of attorney in Swedish and in English are available on the company’s website www.sobi.com and also upon request. If the shareholder is a legal entity, a registration certificate or corresponding document must be enclosed with the form.
- **Please note that a shareholder whose shares are registered in the name of a bank or other nominee must register its shares in its own name to vote.** Instructions regarding this are included in the notice convening the meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (i.e. the postal vote in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The postal voting form, together with any enclosed authorisation documentation, shall be received by Euroclear Sweden AB no later than 2 May 2025. A postal vote can be withdrawn up to and including 2 May 2025 by contacting Euroclear Sweden AB at e-mail generalmeetingservice@euroclear.com. Shareholders who have cast their postal votes electronically through verification with BankID may also withdraw their postal vote at <https://anmalan.vpc.se/euroclearproxy>.

A shareholder who has voted by post may also attend the meeting venue, provided that notice of participation to attend the meeting venue has been made in accordance with the instructions stated in the notice convening the Annual General Meeting. If the shareholder has submitted its postal vote and thereafter attends the meeting venue in person or by proxy, the postal vote will still be valid, provided that the shareholder does not participate in a voting during the meeting or otherwise withdraws its submitted postal vote. If the shareholder chooses to participate in a voting during the meeting, the vote cast at the meeting will replace the previously submitted postal vote with regard to the relevant decision(s). **Please note that the postal vote does not constitute a notice of participation to attend the meeting venue in person or by proxy.**

For complete proposals regarding the items on the agenda, kindly refer to the notice convening the Annual General Meeting and the company’s website www.sobi.com.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear Sweden AB’s website, <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>.

Annual General Meeting in Swedish Orphan Biovitrum AB (publ) on 8 May 2025

The voting options below comprise the proposals submitted by the Board of Directors and the Nomination Committee, included in the notice convening the Annual General Meeting.

<p>2. Election of the chair of the Meeting</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>3. Preparation and approval of the voting list</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>4. Approval of the agenda</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>6. Determination of whether the Meeting has been duly convened</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>10. Resolution regarding adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>11. Resolution regarding appropriation of the company's profit or loss in accordance with the adopted balance sheet</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12. Resolution regarding discharge from liability of the members of the Board of Directors and the CEO</p>
<p>12.1 Christophe Bourdon</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12.2 Annette Clancy</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12.3 Bo Jesper Hansen</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12.4 David Meek</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12.5 Zlatko Rihter</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>

12.6 Helena Saxon Yes <input type="checkbox"/> No <input type="checkbox"/>
12.7 Staffan Schüberg Yes <input type="checkbox"/> No <input type="checkbox"/>
12.8 Filippa Stenberg Yes <input type="checkbox"/> No <input type="checkbox"/>
12.9 Anders Ullman Yes <input type="checkbox"/> No <input type="checkbox"/>
12.10 Mats Lek (employee representative) Yes <input type="checkbox"/> No <input type="checkbox"/>
12.11 Katy Mazibuko (employee representative) Yes <input type="checkbox"/> No <input type="checkbox"/>
12.12 Sara Carlsson (employee representative, deputy) Yes <input type="checkbox"/> No <input type="checkbox"/>
12.13 Åsa Kjellström (employee representative, deputy) Yes <input type="checkbox"/> No <input type="checkbox"/>
12.14 Susanna Rönnback (employee representative, deputy) Yes <input type="checkbox"/> No <input type="checkbox"/>
12.15 Guido Oelkers (CEO) Yes <input type="checkbox"/> No <input type="checkbox"/>
13. Determination of fees to be paid to the members of the Board of Directors and to the auditor
13.1 Fees to be paid to the members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
13.2 Fees to be paid to the auditor Yes <input type="checkbox"/> No <input type="checkbox"/>
14. Determination of the number of directors and deputy directors and auditors and deputy auditors
14.1 The number of directors and deputy directors Yes <input type="checkbox"/> No <input type="checkbox"/>

14.2 The number of auditors and deputy auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
15. Election of the chair, the members of the Board of Directors and the auditor
15.a Christophe Bourdon (director, re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
15.b David Meek (director, re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
15.c Zlatko Rihter (director, re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
15.d Helena Saxon (director, re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
15.e Staffan Schüberg (director, re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
15.f Filipa Stenberg (director, re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
15.g Anders Ullman (director, re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
15.h Iris Loew-Friedrich (director, new election) Yes <input type="checkbox"/> No <input type="checkbox"/>
15.i David Meek (chair, re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
15.j Ernst & Young AB (auditor, re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
16. Resolution on approval of the remuneration report Yes <input type="checkbox"/> No <input type="checkbox"/>
17. Resolution regarding the implementation of a Management Programme and an All Employee Programme in accordance with A.I and A.II, respectively, and hedging arrangements in respect thereof in accordance with B.I and B.II, respectively, and/or C
17.A.I Resolution regarding the implementation of a Management Programme Yes <input type="checkbox"/> No <input type="checkbox"/>
17.A.II Resolution regarding the implementation of an All Employee Programme Yes <input type="checkbox"/> No <input type="checkbox"/>

<p>17.B.I Resolution regarding directed issue of redeemable and convertible series C shares, authorisation for the Board of Directors to resolve to repurchase all issued redeemable and convertible series C shares and transfers of own common shares to the participants of the Management Programme</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>17.B.II Resolution regarding directed issue of redeemable and convertible series C shares, authorisation for the Board of Directors to resolve to repurchase all issued redeemable and convertible series C shares and transfers of own common shares to the participants of the All Employee Programme</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>17.C Should the majority required under item B.I and/or B.II not be reached, resolution regarding equity swap agreement with a third party</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>18. Resolution regarding approval for the Board of Directors to authorise the issuance of new shares and/or convertible bonds and/or warrants</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>19. Resolution regarding transfer of own shares</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>